Smith-Magenis syndrome

Smith-Magenis syndrome (SMS) is a complex developmental disorder caused in most cases (approximately 90%) by a microdeletion on chromosome 17p11.2 encompassing the RAI1 (retinoic acid induced 1) gene, or less commonly by pathogenic variants in the RAI1 gene itself. The condition affects multiple body systems and is characterized by a distinctive pattern of physical, behavioral, and developmental features. Typical facial features include a broad, square-shaped face, deep-set eyes, a flat midface, and a prominent jaw that becomes more apparent with age. Individuals with SMS commonly exhibit intellectual disability of variable degree, significant speech and language delays, and a characteristic behavioral phenotype that includes self-injurious behaviors (such as self-hugging, hand-biting, and insertion of foreign objects into body orifices), attention-seeking behavior, temper outbursts, and a distinctive sleep disturbance marked by an inverted circadian rhythm of melatonin secretion. The sleep disorder is one of the most challenging aspects of SMS, with affected individuals often experiencing difficulty falling asleep, frequent nighttime awakenings, and excessive daytime sleepiness due to an abnormal melatonin cycle. Additional features may include short stature, scoliosis, reduced sensitivity to pain, peripheral neuropathy, hearing loss, ophthalmologic abnormalities (including myopia and iris anomalies), cardiac defects, and renal anomalies. Hypotonia and feeding difficulties are common in infancy. There is no cure for Smith-Magenis syndrome, and management is multidisciplinary and symptom-based. Treatment of the sleep disturbance often involves a combination of controlled-release melatonin administered in the evening and a beta-adrenergic antagonist (such as acebutolol) given in the morning to suppress inappropriate daytime melatonin production. Behavioral interventions, speech and language therapy, occupational therapy, physical therapy, and special educational support are essential components of care. Regular monitoring for associated complications such as cardiac, renal, ophthalmologic, and orthopedic issues is recommended throughout the lifespan.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Smith-Magenis syndrome